Juul Agrees to Pay $438.5 Million in Settlement with 33 States

Sep.07.2022
Juul Agrees to Pay $438.5 Million in Settlement with 33 States
Juul settles with 33 states for $438.5 million and agrees to stop marketing to youth. Funds will go towards anti-vaping efforts.

E-cigarette company Juul has reached a settlement with 33 states, including Connecticut and Puerto Rico, agreeing to halt certain commercial practices, such as marketing to minors, and pay $438.5 million. The states have stated that the compensation will be used to implement bans on e-cigarettes and reduce nicotine activity.


Connecticut Attorney General William Tong stated in a press release that Juul's advertising campaigns have created a new generation of nicotine addicts.


They ruthlessly sell e-cigarette products to minors, manipulate their chemical composition to cater to non-smokers, use inappropriate age verification procedures, and mislead consumers about the nicotine content and addictive potential of their products. The consequences of this improper behavior on public health are still unclear.


The settlement marks the end of a two-year multi-state investigation. Juul has also agreed to refrain from any sponsorship or naming agreements, cease marketing to all youths, and avoid depicting individuals under the age of 35 in their advertisements.


After an appeal in court in June and reaching a temporary agreement with the U.S. Food and Drug Administration (FDA), Juul has continued to sell its products in the U.S. However, due to FDA regulation and legal battles, the company's market share in the vaping industry has significantly dropped. Back in May 2019, Juul held a dominant 75% market share, but according to VaporVoice, as of June 22, it had dropped to around 34.4%, with competitor Vuse narrowly surpassing Juul in the U.S. Meanwhile, the FDA is pushing for Juul to remove all of its products from U.S. shelves, continuing a thorough safety review of the products.


A spate of illnesses associated with the underground electronic cigarette market across the United States has further damaged Juul's public relations efforts.


In 2019, Juul Labs abandoned a campaign worth $11.6 million aimed at reversing San Francisco's ban on e-cigarette sales. In June 2020, the company announced that it was relocating its headquarters from San Francisco to Washington D.C. and expressed a desire to distance itself from the Silicon Valley startup culture and be closer to politicians and regulators.


According to a report by the Associated Press, Juul is still facing nine independent lawsuits from other states. These include a lawsuit filed by California and Los Angeles in November 2019, which focuses on the company's youth-targeted advertising and alleged failure to warn young consumers about the health risks of vaping. In June, a federal judge in San Francisco allowed a lawsuit against Juul Labs and parent company Altria Group Inc. to proceed on various issues related to misleading marketing.


The Associated Press reports that the company is still facing hundreds of individual consumer lawsuits.


A spokesperson for Juul stated in a press release to the Associated Press, "As we continue to fulfill our mission, we remain focused on our future of transitioning adult smokers from the leading cause of preventable death, combustible cigarettes, while combating underage use.


Statement


This article is sourced from compiled third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of its content. The translation of this article is solely intended for communication and research within the industry.


Due to limitations in our translation abilities, the translated article may not accurately reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any statements or positions related to domestic, Hong Kong, Macao, Taiwan, and foreign affairs.


The compiled information belongs to the original media and authors in terms of copyright. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

South Korea Moves Against Synthetic Nicotine Regulatory Gap as Three Companies Face Tobacco Business Act Probe
South Korea Moves Against Synthetic Nicotine Regulatory Gap as Three Companies Face Tobacco Business Act Probe
South Korea’s Ministry of Finance and Economy said on May 4 that it requested the Daejeon Metropolitan Police Agency and Gyeonggi Nambu Provincial Police Agency to investigate three sales companies on suspicion of violating the Tobacco Business Act.
May.06 by 2FIRSTS.ai
WSJ: White House Pushes for More Flavored Vape Approvals as FDA Commissioner Makary Blocks Move
WSJ: White House Pushes for More Flavored Vape Approvals as FDA Commissioner Makary Blocks Move
According to The Wall Street Journal, the White House is pushing to allow more flavored vape products onto the market for the first time in years, but FDA Commissioner Marty Makary opposes the move and has blocked the plan. The report said a memo from Makary’s office prevented authorization of several flavors from vape maker Glas, even after FDA scientific reviewers had supported them.
Apr.20 by 2FIRSTS.ai
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Dick Durbin on May 13 criticized the Trump Administration’s Food and Drug Administration for approving the sale and marketing of fruit-flavored e-cigarettes for the first time, while also allowing some illegal vaping products to remain on the market. He also linked the regulatory shift to the departure of FDA Commissioner Marty Makary, saying White House pressure on regulators to approve tobacco product applications could create serious public-health consequences.
Regulations
May.15
Canada Studies UK-Style “Smoke-Free Generation” Tobacco Ban
Canada Studies UK-Style “Smoke-Free Generation” Tobacco Ban
Canada’s federal health minister, Majorie Michel, said she is looking into legislation that would permanently ban the sale of tobacco products to anyone born after 2008. She said Canada has seen the approach recently proposed in the United Kingdom and is reviewing it with partners. Health Canada previously said the Government of Canada has invested C$66 million annually since 2018 to help Canadians quit smoking and reduce the harms of nicotine addiction.
Apr.29 by 2FIRSTS.ai
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
According to public records from China’s National Intellectual Property Administration, a patent application filed by China Tobacco Yunnan Industrial Co., Ltd. for “cigar flavor granules” was published on May 12, 2026. The filing proposes purifying an ethanol extract of cigar tobacco leaves using LX-8 macroporous resin, followed by encapsulation with maltodextrin and sucrose fatty acid ester to improve smoking comfort, reduce dryness and enhance aroma release stability in reconstituted tobacco.
Jun.10
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13